Source MS Society:
Disease modifying therapy daclizumab (Zinbryta) has been withdrawn from sale worldwide. Its manufacturers took the decision after reports that a number of people taking the treatment developed serious inflammatory brain disorders.
Daclizumab will no longer be available on the NHS. All clinical trials involving the treatment will be stopped. Read on.